预测ANCA相关血管炎复发与感染以优化患者结局:MAINRITSAN试验队列数据
基于MAINRITSAN1和MAINRITSAN2试验中217例接受18个月利妥昔单抗治疗的ANCA相关血管炎患者数据,外部验证复发与感染预测模型。复发模型可预测重大复发(系数1.34,P=0.04),尤其在PR3-ANCA亚组中显著(系数2.76,P=0.01);感染模型对严重感染无生存期有较强预测性能(HR 2.93,95%CI 1.28-6.72,P=0.011)。
要点
- 复发模型在高风险患者中识别出较短的无重大复发生存期(HR 1.91,95%CI 0.97-3.76,P=0.059)。
- 感染模型可识别严重感染高风险患者(HR 2.93,95%CI 1.28-6.72,P=0.011)。
- 复发模型在PR3-ANCA亚组中预测性能更显著,可辅助个体化延长利妥昔单抗决策。
核心结论
- 复发预测模型在外部队列中显示可重复性能,尤其适用于PR3-ANCA患者的风险分层。
- 感染模型预测性能更强,可支持关于延长利妥昔单抗维持治疗的个体化讨论。
研究设计与样本
- 外部验证McClure等人的复发与感染预测模型,主要终点为无复发生存期和无严重感染生存期。
主要发现
- 76例患者发生复发,72个月无复发生存率为55%(95%CI 48-64)。
- 33例患者发生严重感染,72个月累积发生率为20%。
- 复发模型预测重大复发(系数1.34,P=0.04),高风险患者无重大复发生存期较短(HR 1.91,95%CI 0.97-3.76,P=0.059)。
- 复发评分与重大复发风险的关联主要在PR3-ANCA亚组中显著(系数2.76,P=0.01)。
- 感染模型识别的高风险患者无严重感染生存期较短(HR 2.93,95%CI 1.28-6.72,P=0.011)。
关键数值与推荐
- 复发模型因素:男性、年龄>60岁、ANCA阳性、复发性疾病、耳鼻喉受累、泼尼松剂量。
- 感染模型因素:男性、结构性肺病、糖尿病、维持治疗期间感染发生、丙种球蛋白水平。
临床怎么用
- 复发模型可用于临床风险分层,尤其在PR3-ANCA患者中辅助决定是否延长利妥昔单抗维持治疗。
- 感染模型可帮助识别严重感染高风险患者,支持个体化讨论利妥昔单抗延长治疗的获益与风险。
局限性
- 复发模型预测重大复发的HR的95%CI下限接近1且P=0.059,统计学显著性有限。
- 复发评分与重大复发风险的关联主要在PR3-ANCA亚组中显著,其他亚组预测性能未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Long-term follow-up of the MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV). Extending RTX maintenance beyond 18 months may benefit high-risk patients. The aim of this study was to validate relapse and infection prediction models to guide individualized RTX extension decisions. METHODS: Data from 217 patients in the MAINRITSAN1 and MAINRITSAN2 trials treated with RTX for 18 months with follow-up through December 2020 were analysed. We externally validated relapse and infection prediction models from McClure et al. Primary endpoints were relapse-free survival and serious infection-free survival. RESULTS: Relapse occurred in 76 patients, with a 72-month relapse-free survival rate of 55% (95% CI 48-64). Serious infections occurred in 33 patients, with a cumulative 72-month incidence of 20%. The relapse model (factors: male sex, age >60 years, ANCA positivity, relapsing disease, ENT involvement, prednisone dose) predicted major relapse (coefficient 1.34, P = 0.04) and identified high-risk patients with shorter major relapse-free survival (HR 1.91, 95% CI 0.97-3.76, P = 0.059). The relapse score was associated with major relapse risk predominantly within the PR3-ANCA subgroup (coefficient 2.76, P = 0.01). The infection model (factors: male sex, structural lung disease, diabetes, occurrence of infections during maintenance therapy and gammaglobulin level) identified high-risk patients with shorter serious infection-free survival (HR 2.93, 95% CI 1.28-6.72, P = 0.011). CONCLUSION: The relapse prediction model demonstrated reproducible performance in this external validation cohort and may contribute to clinically relevant risk stratification, especially in PR3-ANCA patients. The infection model showed stronger predictive performance and may support individualized discussions regarding RTX extension.
引用
- Delestre F, Charles P, Samson M, et al. Predicting relapse and infection to optimize patient outcomes in ANCA-associated vasculitis: data from the MAINRITSAN trials cohort. Rheumatology (Oxford). 2026. PMID: 42803463. doi:10.1093/rheumatology/keag542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。